r
■Gut and mouth: fluid in the abdomen, gastroesophageal reflux disease, increased salivary secretion, excessive burping and belching, lip inflammation, gastrointestinal disorder, oral pain, abnormal contractions of muscles of the oesophagus, blockage in the stomach and intestine, stomach ulcer, retroperitoneal fibrosis, teeth that crack or break easily, swallowing difficulty, disorder of the salivary gland, haemorrhoids
■Skin: loss of skin colour, peeling skin, excessive body hair, nail shrinkage, excessive sweating,
■General: general condition worsening, weight increase, redness and swelling at the injection site, cancer pain and bleeding, multiple organ failure
■Changes in blood tests: high blood sugar, high blood lipids, changes in blood clotting time, high blood cell counts, low or high protein level
■Other: frequent urination, blood in urine, neck pain, back pain, breast pain, muscle tightness or cramps, joint swelling, limb discomfort, muscle weakness, arthritis inflammation and pain
Rare side effects (affect 1 to 10 users in 10,000) and very rare side effects (affect less than 1 user in 10,000) include:
■acute liver failure
■pancreas infection
■muscle breakdown
■loss of sense of smell
■sun allergy
■loss of a portion of the surface ?skin? of the eye (corneal erosion)
■widespread blood clotting and bleeding
■disease affecting the white matter of the brain
■serious illness with blistering of the skin, mouth, eyes, and genitals
If you experience any of the side effects or if you notice any side effects not listed in this leaflet, please tell your doctor.
If any of the side effects get serious, stop taking Teysuno and tell your doctor immediately.
How should it be stored?
■Keep out of the reach and sight of children.
■Do not use Teysuno after the expiry date which is stated on the outer carton and blister after EXP. The expiry date refers to the last day of the month.
■This medicine does not require any special storage conditions.
■Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.
Further information
What Teysuno contains
■The active substances are tegafur, gimeracil and oteracil. Each hard capsule contains 20 mg tegafur, 5.8 mg gimeracil, and 19.6 mg oteracil monopotassium corresponding to 15.8 mg oteracil.
■The other ingredients are:
Capsule contents: lactose monohydrate, magnesium stearate
Capsule shells: gelatin, titanium dioxide (E171), sodium lauryl sulphate,
talc
Ink: red iron oxide (E172), yellow iron oxide (E172), FD&C Blue No. 2 aluminium lake (E132), carnauba wax, bleached shellac, glyceryl monooleate
What Teysuno looks like and contents of the pack
The hard capsules have a white body and white cap imprinted "TC442" in grey.
Each pack contains either 42 capsules (3 blisters of 14 capsules each) or
84 capsules (6 blisters of 14 capsules each)
Marketing Authorisation Holder
Taiho Pharma Europe, Limited
55 Colmore Row, Birmingham
West Midlands, B3 2AS
United Kingdom
Manufacturer
Brecon Pharmaceuticals Ltd.
Wye Valley Business Park
Hay-on-Wye
Hereford, HR3 5PG
United Kingdom |
